Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130557 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
A Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 536
- Enrollment target
- 20
- Study locations
NCT02130557 is a Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive that has completed, run by Pfizer. The registered enrollment target is 536 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT02130557, a Phase 3 study of Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 536 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
Conditions Studied
Interventions
- DRUG Bosutinib
- DRUG Imatinib
Study Locations (20)
Idaho
- Saint Alphonsus Regional Medical Center, Cancer Care Center - Boise
- Saint Alphonsus Regional Medical Center - Boise
- Saint Alphonsus Caldwell Cancer Care Center - Caldwell
- Saint Alphonsus Medical Center Nampa - Nampa
Louisiana
- Cancer Center of Acadiana at Lafayette General Medical Center - Lafayette
- Lafayette General Medical Center - Lafayette
- LSU Health Sciences Center-Shreveport - Shreveport
- University Health Shreveport - Shreveport
Georgia
- Emory University Hospital - Atlanta
- The Emory Clinic - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Illinois Cancer Center - Chicago
- John H. Stroger, Jr. Hospital of Cook County - Chicago
Indiana
- Indiana Blood and Marrow Transplantation - Indianapolis
- PHARMACY Department Franciscan St. Francis Health ATTN:Jill Leslie, Pharm D - Indianapolis
Massachusetts
- University of Massachusetts Memorial Medical Center, ONC/Research Pharmacy - Worcester
- University of Massachusetts Memorial Medical Center - Worcester
California
- Pacific Cancer Medical Center, Inc. - Anaheim
Hawaii
- Kaiser Permanente Hawaii - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 536 participants |
| Start Date | 2014-07-15 |
| Est. Completion | 2020-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02130557
The ClinicalTrials.gov registry entry for NCT02130557 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 536 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive appearing as the primary indexed condition, and to 2 interventions - of which Bosutinib is the first listed.
NCT02130557 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Idaho, Louisiana, Georgia.
Frequently Asked Questions
What is clinical trial NCT02130557 about?
NCT02130557 is a clinical study titled "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
What is the current status of trial NCT02130557?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 536 participants. The study started on 2014-07-15. Estimated completion is 2020-04-17.
What conditions does trial NCT02130557 study?
This clinical trial studies the following conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive.
What interventions are being tested in trial NCT02130557?
The interventions under investigation include: Bosutinib (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT02130557?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02130557 being conducted?
This trial has 20 study locations across California, Georgia, Hawaii, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.